Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rivastigmine for ECT-induced Cognitive Side Effects (PRECISER)
NCT05768126Phase 4Recruiting
- Start
- Sep 2021
- Primary completion
- Dec 2025
- Modality
- Reversible Covalent Inhibitors, Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
A Phase 4 trial of rivastigmine in major depressive disorder (MDD). Started Sep 2021; status: recruiting.
02
Drugs
rivastigmine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT05768126.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05768126.